es-cushing-steroidogenesis-inhibitors-specific-conditions

name

es-cushing-steroidogenesis-inhibitors-specific-conditions

description

Recommends steroidogenesis inhibitors as second-line treatment after transsphenoidal surgery (TSS) in Cushing's disease, as primary therapy for occult or metastatic ectopic ACTH syndrome (EAS), and as adjunctive cortisol reduction in adrenocortical carcinoma. Use when evaluating CS patients post‑TSS, with occult/metastatic EAS, or ACC; triggers include “persistent hypercortisolism after TSS,” “occult EAS,” and “adjunctive for ACC.”

Steroidogenesis Inhibitors as Second-Line Treatment After TSS, Primary Treatment of Occult/Metastatic EAS, and Adjunctive to Reduce Cortisol in Adrenocortical Carcinoma

STEP 1 — Gather Information

Confirm diagnosis of Cushing’s syndrome (elevated UFC or late‑night salivary cortisol), determine ACTH dependence (measure plasma ACTH), identify etiology (pituitary MRI for CD, chest/abdominal imaging for occult/metastatic EAS, adrenal CT/MRI for ACC), document prior treatments (TSS, radiation/radiosurgery), assess surgical candidacy, and review comorbidities and concomitant medications. Proceed to rule‑in/rule‑out.

STEP 2 — Rule In / Rule Out

Is the patient ACTH‑dependent Cushing’s syndrome (CD or EAS) or adrenal carcinoma (ACC)? If ACTH‑dependent, go to Step 3A; if ACC, go to Step 3B. This binary fork directs the pathway to the appropriate indication.

STEP 3A — Classify or Stratify (ACTH‑dependent)

Classify as either (i) post‑TSS Cushing’s disease (with or without prior RT/radiosurgery) or (ii) occult/metastatic ectopic ACTH syndrome. Endpoint: decide whether steroidogenesis inhibitors are indicated as second‑line after TSS or as primary therapy for EAS.

STEP 3B — Classify or Stratify (Adrenal Carcinoma)

Classify as adrenocortical carcinoma requiring adjunctive cortisol‑lowering therapy. Endpoint: decide to use steroidogenesis inhibitors to reduce cortisol levels in ACC.

STEP 4 — Decide

Initiate a steroidogenesis inhibitor (ketoconazole, metyrapone, or mitotane) according to the specific condition: second‑line after TSS in CD (with or without RT/radiosurgery); primary treatment of occult/metastatic EAS; adjunctive to reduce cortisol in ACC. Titrate dose based on UFC or late‑night salivary cortisol, monitor for adrenal insufficiency and drug interactions, and reassess every 3–6 months.

Clinical Guardrails / Mimics / Pitfalls

Do not use steroidogenesis inhibitors as first‑line when curative surgery is feasible; avoid ketoconazole in severe hepatic impairment or concomitant CYP3A4 substrates without dose adjustment; watch for QT prolongation with metyrapone/mitotane; monitor for adrenal insufficiency (especially with mitotane) and provide stress‑dose glucocorticoids during illness; do not rely solely on hormonal markers for mifepristone‑like agents; avoid in pregnancy unless benefit outweighs risk.

Concrete Clinical Example

A 42‑year‑old woman with persistent Cushing’s disease after TSS (UFC 620 nmol/L, MRI shows 6 mm residual pituitary lesion, not a surgical candidate) is started on ketoconazole 400 mg twice daily. UFC falls to 150 nmol/L after 4 weeks; dose is maintained with monthly UFC and liver‑function checks. She remains eucortisolemic with no adrenal insufficiency after 6 months.

Source: Treatment of Cushing’s Syndrome: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2015, DOI:10.1210/jc.2015-1818